GlassScriptPhysician profile
Lesa R Chopra
NPI 1396954418
$7,490.82
in general payments reported to CMS, 2019-2025
33 companies · $1,686 in 2025
The $1,686 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,154 · 2020: $467 · 2021: $201 · 2022: $1,058 · 2023: $1,310 · 2024: $1,615 · 2025: $1,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,388 · Grant: $188 · Education: $34.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,388.34 |
| Grant | $187.50 |
| Education | $34.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,710.84 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Janssen Biotech, INC. | $1,371.50 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $918.36 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $741.74 | 2019-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $426.17 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $294.29 | 2019-2025 | |
| Celgene Corporation | $238.95 | 2022-2024 | Zeposia |
| Pfizer INC. | $195.27 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $183.79 | 2022-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $168.56 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $139.69 | 2024-2025 | Omvoh, Zepbound |
| Genzyme Corporation | $123.96 | 2022-2025 | |
| Qol Medical, LLC | $110.07 | 2019-2024 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $99.40 | 2023 | Zeposia |
| Merck Sharp & Dohme LLC | $87.87 | 2019-2023 | Dificid |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $87.65 | 2024-2025 | Vowst, Zenpep |
| Regeneron Healthcare Solutions, INC. | $83.21 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $67.32 | 2024-2025 | Iqirvo, Bylvay |
| Ucb, INC. | $58.76 | 2019 | |
| Daiichi Sankyo INC. | $55.64 | 2020-2022 | |
| Evoke Pharma, INC. | $45.90 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $40.23 | 2023 | |
| Boston Scientific Corporation | $38.81 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Phathom Pharmaceuticals, INC. | $34.45 | 2024 | Voquezna |
| Shionogi INC | $29.94 | 2019-2020 | |
| Exact Sciences Corporation | $24.64 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $24.62 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $20.22 | 2020 | |
| Hologic Sales and Service, LLC | $17.25 | 2024 | Myosure Tissue Removal Device |
| Alfasigma USA, INC. | $14.82 | 2020 | |
| Shire North American Group INC | $12.32 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.29 | 2019 | |
| Vivus LLC | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesa Chopra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.